Free Trial
NASDAQ:NAOV

Nanovibronix 5/20/2025 Earnings Report

Nanovibronix logo
$0.90 -0.02 (-2.53%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$0.93 +0.03 (+3.15%)
As of 07/25/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanovibronix EPS Results

Actual EPS
-$3.98
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$1.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nanovibronix's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Nanovibronix Earnings Headlines

NanoVibronix Secures $8 Million Through Securities Agreement
Is this the biggest winner of Trump’s tariffs?
America’s industrial comeback is underway — and it’s bigger than anyone expected. Over $5 trillion has already been pledged to restore U.S. manufacturing. Trump’s tariffs and trade pressure have set off a massive reshoring push, and the flood of investment is still gaining steam. But while everyone’s watching the big names, one under-the-radar company holds the key tech that could make it all work — and potentially benefit the most.
NanoVibronix, Inc. (NAOV) - Yahoo Finance
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:NAOV), through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

View Nanovibronix Profile

More Earnings Resources from MarketBeat